Anti-P2Y12 antibody [S02-2E1]

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

P2Y12 also referred to as the P2Y12 receptor is a G-protein coupled receptor with an approximate mass of 39.6 kDa. It plays a distinct role in platelet aggregation through ADP binding which activates intracellular signaling pathways that result in platelet activation. One finds P2Y12 expressed mainly in platelets and the brain. It is an important target of various antiplatelet drugs which highlights its critical role in physiological frameworks involving thrombosis.

Biological function summary

The P2Y12 receptor is an important component of the platelet activation pathway. When activated it contributes to the amplification of platelet responses to injury. P2Y12 does not function in isolation; it forms part of larger multi-protein complexes essential for thrombus formation. This aggregation process requires synchronized activation of several platelet receptors emphasizing the P2Y12 receptor's critical role in maintaining hemostasis through cellular signaling.

Pathways

The P2Y12 receptor is integral to the thrombin and ADP signaling pathways functioning in tandem with other proteins such as the P2Y1 and CXCR4 receptors to execute cellular responses. These pathways facilitate platelet shape change secretion and aggregation therefore solidifying their place within the broader scope of hemostatic responses. Coordination with such protein partners ensures efficient propagation of signals necessary for rapid platelet activation and clot formation.

P2Y12 is closely linked to cardiovascular diseases particularly thrombosis and myocardial infarction. Its involvement in excessive platelet aggregation makes it a significant target for therapeutic agents like the P2Y12 receptor blockers. The receptor also interacts with proteins like glycoprotein IIb/IIIa in the clotting process providing potential pathways for therapeutic intervention. Dysregulation of P2Y12 function presents a risk for unwarranted thrombotic events highlighting the importance of P2Y12 antagonists such as ticagrelor in clinical settings to manage such conditions effectively.